FSD Pharma Inc. (HUGE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
FSD Pharma Inc. (HUGE) trades at $0.0899 with AI Score 44/100 (Grade C). FSD Pharma Inc. is a pharmaceutical research and development company focused on developing treatments for neuropsychiatric disorders and autoimmune diseases. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for HUGE: HUGE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HUGE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HUGE: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
FSD Pharma Inc. (HUGE) Healthcare & Pipeline Overview
FSD Pharma Inc. is a pharmaceutical R&D company concentrating on neuropsychiatric and autoimmune disease treatments. Their pipeline includes FSD-201 for COVID-19 (Phase II trials), Lucid-PSYCH for neuropsychiatric disorders, and Lucid-MS for multiple sclerosis, positioning them within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for HUGE?
FSD Pharma Inc. is a high-risk, high-reward investment opportunity in the pharmaceutical sector. The company's value hinges on the successful development and commercialization of its drug pipeline, particularly FSD-201, Lucid-PSYCH, and Lucid-MS. Positive results from ongoing Phase II clinical trials for FSD-201 could serve as a significant catalyst, driving investor interest and potentially leading to partnerships or acquisitions. The successful development of Lucid-PSYCH and Lucid-MS could open up new revenue streams in the neuropsychiatric and autoimmune disease markets. However, the company faces significant risks, including the uncertainty inherent in drug development, regulatory hurdles, and the need for substantial capital to fund its research and clinical trials. With a market cap of $0.00B and a negative P/E ratio of -0.19, FSD Pharma is a speculative investment that requires careful consideration of its potential upside and downside.
Based on FMP financials and quantitative analysis
HUGE Key Highlights
- FSD-201 is in Phase II clinical trials for the treatment of COVID-19 disease.
- Lucid-PSYCH is being developed for the potential treatment of neuropsychiatric disorders, such as depressive disorder.
- Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models of multiple sclerosis.
- The company was founded in 1998 and is headquartered in Toronto, Canada.
- FSD Pharma operates in the Drug Manufacturers - Specialty & Generic industry.
Who Are HUGE's Competitors?
HUGE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACOR Acorda Therapeutics, Inc. | $0.66 | -24.02% | 42 | |
| BFRI Biofrontera Inc. | $1.08 | +2.86% | $13.8M | — |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.14 | +0.07% | $40.3M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HUGE's Key Strengths?
- Novel drug candidates in development.
- Focus on unmet medical needs.
- Patented technologies.
- Experienced research and development team.
What Are HUGE's Weaknesses?
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
- Lack of commercial infrastructure.
- High risk of drug development failure.
What Could Drive HUGE Stock Higher?
- Results from Phase II clinical trials for FSD-201 in COVID-19 treatment.
- Progress in preclinical and clinical development of Lucid-PSYCH for neuropsychiatric disorders.
- Advancement of Lucid-MS towards clinical trials for multiple sclerosis.
- Strategic partnerships and collaborations to expand product pipeline.
- Potential acquisitions of complementary assets or technologies.
What Are the Key Risks for HUGE?
- Financial-distress signal — its Altman Z-Score of -16.81 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain positive results in clinical trials.
- Regulatory delays or rejection of drug applications.
- Competition from established pharmaceutical companies.
- Dependence on securing additional funding to support research and development.
- Patent challenges or expirations.
What Are the Growth Opportunities for HUGE?
- Expansion of FSD-201 into additional indications: Beyond COVID-19, FSD-201 may have potential applications in treating other inflammatory conditions. The market for anti-inflammatory drugs is substantial, estimated at billions of dollars annually. Successful expansion into new indications could significantly increase FSD Pharma's revenue potential. This would require further clinical trials and regulatory approvals, with a potential timeline of 3-5 years.
- Development and commercialization of Lucid-PSYCH: The neuropsychiatric disorders market is a large and growing market, with a significant unmet need for new and effective treatments. Successful development and commercialization of Lucid-PSYCH could generate substantial revenue for FSD Pharma. This would involve completing preclinical and clinical trials, obtaining regulatory approvals, and establishing a commercial infrastructure, with a potential timeline of 5-7 years.
- Advancement of Lucid-MS for multiple sclerosis: Multiple sclerosis is a chronic autoimmune disease that affects millions of people worldwide. Lucid-MS has shown promise in preclinical studies, and further development could lead to a breakthrough therapy for MS. The MS market is estimated at billions of dollars annually, representing a significant opportunity for FSD Pharma. This would require extensive clinical trials and regulatory approvals, with a potential timeline of 7-10 years.
- Strategic partnerships and collaborations: FSD Pharma could pursue strategic partnerships and collaborations with other pharmaceutical companies or research institutions to accelerate the development and commercialization of its drug candidates. These partnerships could provide access to additional funding, expertise, and resources, enhancing the company's growth prospects. The timeline for establishing such partnerships is variable, depending on the specific opportunities that arise.
- Acquisition of complementary assets or technologies: FSD Pharma could acquire complementary assets or technologies to expand its product pipeline and enhance its research and development capabilities. This could involve acquiring other pharmaceutical companies, licensing new drug candidates, or investing in innovative technologies. The timeline for such acquisitions is variable, depending on market conditions and available opportunities.
What Opportunities Does HUGE Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Acquisition of complementary assets.
- Positive clinical trial results.
What Threats Does HUGE Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles.
- Patent expirations.
- Unfavorable clinical trial results.
What Are HUGE's Competitive Advantages?
- Patented new chemical entities (NCEs) like Lucid-MS.
- Proprietary research and development capabilities.
- Clinical data supporting the efficacy of drug candidates.
- Expertise in neuropsychiatric and autoimmune disease research.
What Does HUGE Do?
Founded in 1998 and headquartered in Toronto, Canada, FSD Pharma Inc. operates as a pharmaceutical research and development company. The company is dedicated to identifying and developing novel treatments for significant unmet medical needs, particularly in the fields of neuropsychiatric disorders and autoimmune diseases. FSD Pharma's lead drug candidate, FSD-201, is currently in Phase II clinical trials, evaluating its efficacy in treating COVID-19. Beyond FSD-201, the company is developing Lucid-PSYCH, a psychoactive molecule with potential applications in treating neuropsychiatric disorders, including depressive disorder. Additionally, FSD Pharma is advancing Lucid-MS, a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models of multiple sclerosis. FSD Pharma aims to leverage its research and development capabilities to create innovative therapies that address critical healthcare challenges.
What Products and Services Does HUGE Offer?
- Develop pharmaceutical treatments for neuropsychiatric disorders.
- Research and develop drugs for autoimmune diseases.
- Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
- Seek regulatory approvals for new drugs from health authorities.
- Explore strategic partnerships to expand product pipeline.
- Focus on innovative therapies to address unmet medical needs.
How Does HUGE Make Money?
- Develop and patent novel pharmaceutical compounds.
- Conduct preclinical and clinical research to validate drug efficacy and safety.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Potentially manufacture and market drugs directly, pending regulatory approvals.
What Industry Does HUGE Operate In?
FSD Pharma Inc. operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and a constant drive for innovation. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in pharmaceutical research. Companies like FSD Pharma focus on developing niche products and innovative therapies to gain a competitive edge. The industry faces challenges such as stringent regulatory requirements, pricing pressures, and the need for significant investment in research and development. Competitors include companies like ACOR, BFRI, BHHKF, CNNA, and CVGRF, each vying for market share in specific therapeutic areas.
Who Are HUGE's Key Customers?
- Pharmaceutical companies seeking to in-license novel drug candidates.
- Patients suffering from neuropsychiatric disorders.
- Patients with autoimmune diseases like multiple sclerosis.
- Healthcare providers prescribing medications for these conditions.
F-Score 2/9Financial Health
FSD Pharma Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.81 places it in the distress zone, a signal of elevated financial risk.
How FSD Pharma Inc. Is Valued
Relative to its peer group, HUGE's quantitative score of 44/100 is below the peer average of 57/100.
HUGE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has been trending positively, with discussions highlighting innovative developments in their product pipeline.
- FSD Pharma's strategic partnerships have garnered attention, positioning the company to leverage new market opportunities effectively.
- The growing interest in the cannabis sector has revitalized discussions around companies like FSD Pharma, attracting new investor interest.
Bear Case
- Concerns over regulatory changes in the cannabis industry have led to increased skepticism among some investors, impacting overall sentiment.
- Recent earnings reports have shown mixed results, raising questions about the company's ability to achieve sustainable growth.
- Social media sentiment has seen a notable shift, with bearish comments gaining traction, reflecting a more cautious outlook among retail investors.
- Increased competition in the cannabis space could pose challenges for FSD Pharma, as new entrants may dilute market share and investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HUGE Latest News
-
Buyers Push Micron Stock To Nose-Bleed Levels As Earnings Approach; Darden, FedEx Results Also On Tap
Investor's Business Daily · Jun 18, 2026
HUGE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HUGE.
Price Targets
Wall Street price target analysis for HUGE.
HUGE MoonshotScore
What does this score mean?
The MoonshotScore rates HUGE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Zeeshan Saeed
CEO
Zeeshan Saeed serves as the CEO of FSD Pharma Inc. His background includes experience in managing and leading teams within the pharmaceutical and healthcare sectors. He is responsible for overseeing the company's strategic direction, research and development efforts, and overall operations. His leadership is focused on advancing FSD Pharma's drug pipeline and creating value for shareholders.
Track Record: Under Zeeshan Saeed's leadership, FSD Pharma has focused on advancing its key drug candidates, including FSD-201, Lucid-PSYCH, and Lucid-MS, through preclinical and clinical development stages. He has overseen the company's efforts to secure patents and establish strategic partnerships. His tenure has been marked by a focus on innovation and addressing unmet medical needs.
FSD Pharma Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for HUGE?
HUGE holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. FSD Pharma Inc. is a pharmaceutical research and development company focused on developing treatments for neuropsychiatric disorders and autoimmune diseases. Their lead candidate, FSD-201, is …
What does FSD Pharma Inc. do?
FSD Pharma Inc. is a pharmaceutical research and development company focused on developing treatments for neuropsychiatric disorders and autoimmune diseases. The company's lead candidate, FSD-201, is in Phase II clinical trials for COVID-19. Additionally, FSD Pharma is developing Lucid-PSYCH for neuropsychiatric disorders and Lucid-MS for multiple sclerosis. The company aims to address unmet medical needs through innovative therapies and strategic partnerships, operating within the specialty and generic drug manufacturing sector.
What are the main risks for HUGE?
FSD Pharma Inc. faces several significant risks inherent in the pharmaceutical industry. These include the risk of failure in clinical trials, which could halt the development of key drug candidates. Regulatory hurdles and potential delays in obtaining approvals pose another risk. Competition from larger, more established pharmaceutical companies could limit market share.
What are the key factors to evaluate for HUGE?
FSD Pharma Inc. (HUGE) holds an AI score of 44/100 (low). Not financial advice.
How frequently does HUGE data refresh on this page?
HUGE's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HUGE's recent stock price performance?
FSD Pharma Inc. (HUGE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidates in development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HUGE overvalued or undervalued right now?
FSD Pharma Inc. (HUGE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HUGE before investing?
Before investing in FSD Pharma Inc. (HUGE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HUGE to a portfolio?
Key strength of FSD Pharma Inc. (HUGE): Novel drug candidates in development. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.